Compare Johnson & Johnson (JNJ) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Ralph Lauren Corp — how do they compare? Johnson & Johnson trades at $250.23 (market cap $598.96B), while Ralph Lauren Corp trades at $383.63 (market cap $22.41B). The key difference: Johnson & Johnson is far larger — about 26.7× Ralph Lauren Corp's market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JNJ | RL | |
|---|---|---|
Market Cap | $598.96B | $22.41B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $267.24 | $414.25 |
52-Week Low | $164.36 | $283.34 |
Enterprise Value | $631.90B | $23.35B |
Dividend Yield | 2.15% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Ralph Lauren (RL) trades at $376.55, down 1.03% on the day, with a neutral technical signal and key support at $370. The company demonstrates strong fundamentals, with revenue growing to $7.08B in 2025 and net income of $742.9M, supported by a 69.87% gross margin and consistent earnings beats. Analyst consensus is bullish with a $445.71 price target, and recent news highlights brand strength and digital expansion.
The outlook for RL is positive, driven by earnings momentum and strategic initiatives, though premium valuation and market volatility present risks. Upside potential exists if the company maintains its growth trajectory and meets Q2 2026 EPS expectations of $4.26.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
